肿瘤突变负荷作为一种泛癌种免疫治疗生物标志物：局限性和趋同的潜力。
Tumor Mutational Burden as a Pan-cancer Biomarker for Immunotherapy: The Limits and Potential for Convergence.
机构信息
Division of Thoracic Oncology, European Institute of Oncology, IRCCS, Milan, Italy.
Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.
出版信息
Cancer Cell. 2020 Nov 9;38(5):624-625. doi: 10.1016/j.ccell.2020.10.019.
PMID:33171127
Abstract
A recent study in The Lancet Oncology reports that high tumor mutational burden (TMB) is associated with response to anti-PD-1 pembrolizumab, leading to the second FDA approval of a tissue-agnostic predictive biomarker for immunotherapy in solid tumors. This is a step forward in realizing the full potential of cancer immunotherapy.
摘要
《柳叶刀肿瘤学》的一项最新研究报告称，高肿瘤突变负担（TMB）与抗 PD-1 派姆单抗的应答相关，这导致了第二个 FDA 批准的实体瘤免疫治疗的组织不可知预测性生物标志物。这是在实现癌症免疫治疗的全部潜力方面迈出的一步。
Zotero 插件